Wells Fargo’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Wells Fargo’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-32,479	Closed	-$749K	–	7767
2020 Q4	$749K	Buy	32,479 +22,979	+242%	+$291K	﹤0.01%	4235
2020 Q3	$97K	Sell	9,500 -1,628	-15%	-$21.8K	﹤0.01%	5280
2020 Q2	$166K	Sell	11,128 -10,240	-48%	-$158K	﹤0.01%	5006
2020 Q1	$260K	Buy	21,368 +9,225	+76%	+$147K	﹤0.01%	4509
2019 Q4	$192K	Buy	12,143 +7,643	+170%	+$97.5K	﹤0.01%	4976
2019 Q3	$55K	Buy	+4,500	New	+$51K	﹤0.01%	5538

Wells Fargo's PRVL Position: Q1 2021 in Review

Wells Fargo sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 32,479 shares — an estimated $749K sold.

Wells Fargo first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $749K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Wells Fargo reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Wells Fargo sold 32,479 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $749K.
Wells Fargo first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
Wells Fargo's Prevail Therapeutics Inc. Common Stock position peaked at $749K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Wells Fargo's 13F filing for Q1 2021, filed 13 May 2021.